The second quarter presented Publix with some challenges resulting in a slight comparable-sales decline as total sales and earnings gained.
Net earnings were $1.66 billion versus $1.38 billion in the year-before quarter as earnings per share were 52 cents versus 42 cents, the company reported. With the effect of net unrealized gains on equity securities in 2026 and 2025 excluded, net earnings for the three months would have been $1.06 billion, or 33 cents per share, compared to $1.04 billion, or 32 cents per share, in the year-previous period.
Comparable sales decreased 0.5% in the quarter year over year, Publix maintained. Overall, sales came in at $15.7 billion versus $15.6 billion in the year-earlier period.
The sales increase was lower than would have been the case due to the impact from the Medicare maximum fair price change effective January 1, which reduced prices for 10 drugs. Sales also were hit by economic conditions pressuring consumer spending, Publix noted.
Effective August 1, Publix’s stock price slipped from $20.45 per share to $19.60 per share. Publix stock is not publicly traded and is sold only to current Publix associates and members of its board of directors.
